REPL (Replimune Group, Inc.) — Stock Analysis, Catalysts & AI Research

Replimune Group, Inc.

$12.06

Health CareBiotechnology

The Read: 9% after Q4 2025 results eased cash runway fears, then surged about 81.

REPL

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Replimune Group, Inc.

$12.06

Health CareBiotechnology

The Read: 9% after Q4 2025 results eased cash runway fears, then surged about 81.

REPL

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Start your free trial to unlock active Expected Moves for REPL

Expected Moves

Replimune Group, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Start your free trial to unlock active Expected Moves for REPL

Expected Moves

Replimune Group, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow